Abstract
Background: In the new era of risk-based prostate cancer (PCa) screening, stratifying men by their individual risk is crucial. Our study aims to integrate anamnestic, life-style and molecular data to minimize unnecessary second-level investigations (SLI) and improve detection of clinically significant PCa (ISUP>1). Methods: Since 2021, within the DP3 study, we collected plasma samples, recent clinical history, familiarity for cancer, and life-style information from: 421 men who underwent PSA testing and digital rectal examination (longitudinal sampling every 6 months), 421 men with suspected PCa, before diagnostic biopsy and 62 men with PCa diagnosis, before radical prostatectomy. Fifty sphingolipids were tested in the plasma of 393 men by targeted lipidomics. Univariable logistic regression analysis was applied to identify the variables associated with PCa. Multivariable penalized logistic regression analysis with 10-fold cross validation was run on different subgroups of the total cohort to build each time 10 models on 9/10 of the samples and assess their performance on the 10 test sets. Results: PSA levels, age, cardiovascular diseases (CVD), number of medications, hypertension, sedentariness, and three sphingolipids (Gb3.24, Cer.20, Cer.24.1) showed a significant association with clinically significant PCa in univariable analysis of the entire cohort. Penalized logistic regression modelling consistently selected hypertension, CVD, PSA, age and five sphingolipids (HexCer.20, Cer.20, HexCer.24.1, GM3.24.1, DHCer.24) as key variables to accurately classify PCa (average ROC AUC on the 10 test sets: 0.92 vs 0.85 for PSA). In men recalled for SLI, PSA showed poor discriminatory ability, but PSA, age, CVD, SM.16, HexCer.20, HexCer.24.1, DHS1P, and DHCer.24 were consistently selected by 10/10 models (average ROC AUC: 0.83 vs 0.65 for PSA). Cer.20 and CVD or CVD alone were key variables also for the discrimination of ISUP>1 PCa within the entire cohort or within men recalled for SLI, respectively. Conclusions: The evaluation of individual risk factors and circulating sphingolipids may allow for a more accurate identification of PCa in the context of tailored screening.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The DP3 study was funded by Compagnia di San Paolo (CP-N; FG); Rete Oncologica del Piemonte e della Valle di Aosta; the National Plan for Complementary Investments to the NRRP, project D34H-Digital Driven Diagnostics, prognostics and therapeutics for sustainable Health care (project code: PNC0000001), Spoke 4 financed by the Italian Ministry of University and Research (MS); Fondazione CRT (CP-N; MM-G; PO; IG; GC).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The observational clinical protocol called DP3 coordinated by FEET was approved by the Novara ethical committee (AOU Maggiore della Carita') in September 2020 (Prot. N. 968/CE 07/09/2020, integration Prot. N.263/CE, 10/03/2021), in accordance with the Declaration of Helsinki Ethical Principles for Medical Research involving Human Participants. The MH ethical committee (AOU Citta' della Salute e della Scienza) in Turin approved the DP3 study in January 2022 (Prot. N. 521/2021, 10/01/2022).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
